Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: The present invention relates to compounds of formula I: in which X1, X2, X3, Y1, Y2, Y3, R1, R2, R3a, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: Provided are polymerization processes, comprising melt polymerizing a carbonate and a dihydroxy compound in the presence of an amount of a beta organic catalyst so as to give rise to a polycarbonate product, wherein the amount of beta organic catalyst comprises at least one onium salt and also comprises tetraphenyl phosphonium oxide (TPPO), and wherein the TPPO represents less than about 0.3 weight % of the sum of the weights of the at least one onium salt and the TPPO in the amount of beta organic catalyst.

Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2, R4a, R5b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: An electronic device capable of communicating by Li-Fi and comprising:—at least one light emitting diode (4) intended to emit Li-Fi signals;—energy recovery means (10) intended to recover thermal energy produced by the light emitting diode and to generate, from the recovered thermal energy, a first electrical energy supply of the electronic device.

Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: Aspects of the embodiments are directed to systems, methods, and apparatuses to determine transmission equalization coefficients (TxEQs) for one or more lanes of a high speed serial link. Embodiments include determining a jitter tolerance for each TxEQ of a plurality of TxEQs for a lane of the link. The jitter tolerance for each TxEQ for the lane is based on a level of jitter induced on the lane to detect a number of errors on the lane; determining a voltage (VOC) margin for each TxEQ for the lane, wherein the voltage margin for the lane is based on a voltage corners test applied to the lane to detect a number of errors on the lane at a high voltage point and a low voltage point; determining a TxEQ that provides maximum jitter tolerance and based on the determined lowest voltage margin; and using the TxEQ for the lane during operation.

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: A Spontaneous Area Network (SPAN) is formed by mobile and fixed nodes using wireless transmission links between nodes, usually in a nearby geographical area. Applications allow users to create, join, leave, and manage SPANs and groups in a SPAN. Automatic procedures allow nodes to join other SPANs. Transmission power of the wireless network interface is dynamic, varying depending on battery level, type of information to transmit, state and topology of the network. A delay tolerant object layer abstraction creates, modifies, deletes, publishes, and handles Delay Tolerant Distributed Objects (DTDOs). A Patient Transport Protocol (PTP) ensures a reliable transport of information through the network while avoiding congestion conditions. An aggressive and explosive network protocol (AGENET) has routing and forwarding capacities and uses datagrams to establish communication between different nodes of the SPAN.

Abstract: The present invention describes a low-cost apparatus for selectively brewing stronger coffee. The invention provides for a switch and two circuits integral to the coffee maker whereby the user can manually select between a regular brew and a strong brew accomplished by adding in a second circuit.

Abstract: The invention disclosed relates to systems for wirelessly communicating with a household appliance whereby a user is able to play audio through the household appliance. Embodiments of the related appliance apparatus include appliances, such as a coffee maker, that further include integral Bluetooth communication, digital audio processing and amplification, as well as an integrated speaker for output of the processed and amplified audio.

Abstract: The invention discussed herein discloses an apparatus for use in a brewing appliance. The apparatus is configured to receive two or more standard beverage pods and a multi-point water dispensing manifold delivers the water to the pods for steeping of the liquid. By way of example, the apparatus disclosed as the present invention may be used to brew two or more standard beverage pods, simultaneously, as may be desired by the user.

Abstract: The invention disclosed herein is directed to a smart slow cooker, system, and related methods for heating food to at least 50 degrees centigrade within at most two hours, then adjusting the power to a lower setting for the remainder of the desired cooking time.

Abstract: The invention described discloses an appliance system that is specially configured to receive a specific food item, for example a burrito or a 12-inch pizza, cook it according to a predetermined set of temperature and time parameters, then switch to a keep warm mode to ensure that the food item does not burn if left unattended. Several key elements differentiate this appliance from other similar appliances, namely, the unit self-monitors, cooks food items and minimizes the risk of burning the user or flammable materials around the unit.